|
| Perspective From Industry Leaders |
|
|
| BIO Notebook: Amgen CEO Blasts IRA, Novo Nordisk Stays Cautious On BD, And More | ‘That’s A Much Broader Statement’: Hikma Grilled In Amarin Vascepa Skinny-Label Appeal |
|
Insights from Day Three of the BIO International Convention in San Diego include Amgen CEO Bob Bradway... |
Hikma may have succeeded in dismissing Amarin’s induced infringement claim against the firm over Hikma’s skinny... |
| Licensing & Collaboration Agreements |
|
|
| BIO Roundup: Deal-Making Tips And Tricks | BioBytes: AI-Related Deals In Q1 2024 |
|
Key insights from the recent the BIO International Convention in San Diego, US. |
BioBytes presents an overview of AI-related deals in Q1 2024. This is the first in a recurring series of quarterly deal... |
| Next Gen R&D |
|
|
| ADDF Leaders Discuss Future Strategies In Alzheimer’s Research And Crucial Role Of Diagnostic Markers | ‘Mental Health, Beyond Medication’: Motif Targets Depression With Minimally Invasive DOT |
|
Medtech Insight talked to two leaders at the Alzheimer’s Drug Discovery Foundation about current therapies... |
Motif’s “pea-sized” Digitally programmable Over-brain Therapeutic (DOT) requires 20 minutes to implant... |
| Clinical Trials |
|
|
| What Pandemic? Clinical Trials Shake The COVID-19 Dust Off Their Feet | Jazz’s Suvecaltamide Fails In Tremor Trial, But Parkinson’s Study Continues |
|
Industry-sponsored clinical trial activity has returned to pre-pandemic trends now that the turmoil of COVID-19... |
A Phase IIb trial evaluating suvecaltamide failed to show a statistically significant benefit versus placebo on... |
|
|
|
Citeline Contact Poornachandra Tejasvi .K, 
|
IPA Contact Name: Hari Pranav K |